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Association of serum C-reactive protein and
erythrocyte sedimentation rate with muscle strength
in patients with knee osteoarthritis
Diana C. Sanchez-Ramirez1,2,3, Marike van der Leeden1,3, Martin van der Esch1,
Martijn Gerritsen4, Leo D. Roorda1, Sabine Verschueren5, Jaap van Dieën2,6,
Joost Dekker1,3,7 and Willem F. Lems4,8
Abstract
Objective. To examine the association of serum CRP and ESR with muscle strength in patients with
knee OA.
Methods. Cross-sectional data from 285 patients with knee OA from the Amsterdam Osteoarthritis
(AMS-OA) cohort were analysed. CRP (mg/l) and ESR (mm/l) were measured in serum from patients’
blood samples and the values were dichotomized for the analyses. Strength of quadriceps and hamstring
muscles was assessed using an isokinetic dynamometer. Univariable and multivariable linear regression
analyses were used to assess the association of CRP and ESR with muscle strength, adjusting for relevant
confounders.
Results. Elevated levels of serum CRP (=0.10; P = 0.04) and ESR (=0.12; P = 0.02) were associated
with lower muscle strength after adjustment for age, sex, comorbidities and NSAID use. The associations
were no longer significant when BMI was incorporated in the adjusted model.
Conclusion. Inflammation might influence muscle strength in patients with knee OA. Moreover, the link
between inflammation and obesity might explain the effect that BMI has in the associations between
inflammatory markers (i.e. CRP and ESR) and muscle strength.
Key words: knee osteoarthritis, inflammatory markers, C-reactive protein, erythrocyte sedimentation rate,
muscle strength.
Introduction
OA is a highly prevalent disease that has been associated
with decreased muscle strength and activity limitations [1,
2]. Even though OA has traditionally been considered a
non-inflammatory disease compared with RA, evidence
has recently shown a low grade of inflammation mainly
associated with synovitis in this group of patients [36].
However, in contrast to patients with well-known inflam-
matory diseases like RA in which inflammatory markers
such as CRP and ESR are usually elevated, in patients
with OA only slight or moderate elevations of inflammatory
markers (i.e. CRP and ESR) have been described [711].
Previous studies have analysed the relationship of CRP
and ESR values with pain, global severity/progression of
the disease and activity limitations in patients with OA
[9, 10, 12, 13]. Moreover, ESR but not CRP was inversely
correlated with hand grip strength (P< 0.005) [10].
However, there are still scarce data on the association
of these inflammatory markers and muscle strength in
this group of patients. In older adults and in patients
with RA, increased circulating levels of inflammatory cyto-
kines, such as IL-6 and TNF-a, have been associated with
sarcopenia and muscle weakness [1417]. Further
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evidence has suggested that elevated levels of circulating
inflammatory markers (i.e. cytokines) might be involved in
muscle atrophy and impaired muscle regeneration in older
adults [18, 19]. In patients with OA, a recent study has
reported a relationship between elevated markers of
inflammation (IL-6) in vastus lateralis biopsies and knee
muscle weakness (extensors and flexors) [20]. In contrast,
using plasma inflammatory markers (IL-6), inflammation
and knee extensor strength were not associated in this
group of patients [21]. In conclusion, the relationship
between inflammation and muscle strength has hardly
been studied in patients with OA, and the results have
been conflicting.
Based on the hypothesis that inflammation
might explain some of the decrease in muscle strength
that is usually found in patients with OA, the purpose of
this cross-sectional study was to examine the association
of serum inflammatory markers (i.e. CRP and ESR)
with muscle strength in patients with established knee OA.
Patients and methods
Subjects
Two hundred and eighty-five participants from the
Amsterdam Osteoarthritis (AMS-OA) cohort (179 females,
106 males) with unilateral or bilateral diagnosis of knee OA
according to the ACR [22] were included in this study [23].
The AMS-OA is a cohort of patients with OA of the knee
and/or hip according to the ACR criteria [22, 24], who have
been referred to an outpatient rehabilitation centre (Reade,
Centre for Rehabilitation and Rheumatology, Amsterdam,
the Netherlands). Participants were assessed by rheuma-
tologists, radiologists and rehabilitation physicians. Total
knee replacement, RA or any other form of inflammatory
arthritis (i.e. crystal arthropathy, septic arthritis, SpA) were
considered exclusion criteria. Demographic, radiographic,
biomechanical, clinical and psychosocial factors related to
OA were assessed. All the participants provided
written inform consent according to the Declaration of
Helsinki. The study was approved by the Slotervaart
Hospital/Reade Institutional Review Board.
Measures
Inflammatory markers
Inflammatory markers were measured in serum from
patients’ blood samples. CRP (mg/l) was processed
immunoturbidimetrically using CRPLX test kits [25, 26]
and the Roche Cobas-6000 analyser (Roche Diagnostics
GmbH, Mannheim, Germany). ESR values were deter-
mined by the standard Westergren method [27]. In this
method, EDTA anti-coagulated blood samples were pre-
diluted with saline solution and aspirated into the
Westergren pipette graduated from 0 to 200 mm. The
rate at which red blood cells sedimented in 1 h was mea-
sured and reported in mm/h.
Muscle strength
Knee muscle strength was assessed using an isokinetic
dynamometer (EnKnee, Enraf-Nonius, Rotterdam, the
Netherlands) [28]. An initial practice attempt was used
for the patients to get familiar with the required move-
ments. The patients performed three maximal test repeti-
tions to measure the isokinetic strength of the quadriceps
and hamstrings for each knee, at 60/s. Mean quadriceps
and hamstring muscle strength per leg was calculated (in
Nm), and divided by the patient’s weight (in kg) [23, 29].
This measurement (in Nm/kg) has shown excellent intra-
rater reliability [intraclass correlation coefficient (ICC)
0.93] in knee OA patients [30].
Potential confounders
Demographic data (i.e. age and gender) were recorded.
Information related to comorbidities was collected with
the Chronic Illness Rating Scale [31]. This instrument
allows the gathering of information related to 13 body sys-
tems, scoring from 0 (none) to 4 (extremely severe) accord-
ing to the severity of the condition. The number of diseases
on which the patients scored a severity of 52 was calcu-
lated and incorporated in the analyses. NSAID use was
dichotomized (yes, no) if the patients were taking NSAID
medicines or not. BMI was calculated as body mass in
kilograms divided by height in squared metres (kg/m2).
Statistical analysis
Descriptive statistics were used to characterize the study
population. Percentages were used for categorical vari-
ables, means (S.D.s) and medians [inter-quartile ranges
(IQRs)] for continuous variables. Linear regression ana-
lyses were used to analyse the association of inflamma-
tory markers (CRP and ESR) as independent factors with
muscle strength (Nm/kg) as dependent factor. CRP was
dichotomized as 0 if levels in serum were low to intermedi-
ate (43 mg/l) and 1 if levels were elevated (>3 mg/l). This
cut-off level was chosen according to previous studies in
patients with OA [11, 32]. A sensitivity analysis using CRP
cut-off point of 2 mg/l was carried out (data not shown).
ESR was dichotomized following the classification criteria
of low to normal rate 0 (<20 mm/h) and elevated rate 1
(520 mm/h) [24].
First, regression analyses were used to analyse the
association of CRP and ESR with muscle strength
(crude models). Secondly, single confounding effects of
potentially relevant variables (i.e. age, gender, comorbid-
ities, NSAID use and BMI) were determined (Table 1).
Thirdly, multivariable regression models adding one rele-
vant confounding variable at a time were analysed (Table
2). Statistical significance was accepted at P< 0.05. All
analyses were performed using SPSS software, version
18.0 (SPSS, Chicago, IL, USA).
Results
Descriptives
Almost two-thirds (63%) of the group (n = 179) were
women and the mean (S.D.) age was 61.7 (7.3) years.
The median (IQR) of CRP and ESR in the study group
was 2 mg/l (24) and 9 mm/h (415), respectively. A total
of 26% of the study population had CRP levels >3 mg/l
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(n = 73), with a mean (S.D.) of 7.41 (7.34) mg/l. ESR was
520 mm/h in 18% of the patients (n = 51), with a mean
(S.D.) of 27.00 (7.83) mm/h. In the non-elevated CRP and
ESR groups the mean (S.D.) were 1.62 (0.83) mg/l and 7.90
(4.73) mm/h, respectively. The mean (S.D.) muscle strength
of the study population was 0.9 (0.4) Nm/kg. Further
demographic and clinical characteristic data are shown
in Table 3.
Association of inflammatory markers (CRP and ESR)
with muscle strength
The relative symmetry of distribution of muscle strength
according to elevated or non-elevated inflammatory mar-
kers are presented in the Figs 1 (CRP) and 2 (ESR).
Table 1 shows the crude association of CRP and ESR
with muscle strength. Elevated CRP (crude =0.13;
P = 0.03) and ESR (crude =0.21; P< 0.001) values
were significantly associated with lower muscle strength.
Simple adjusted models analysed the influence of each
potential confounder (i.e. age, gender, comorbidities,
NSAID use and BMI) at the time. In these simple
models, gender and BMI were the factors that most
affected the crude models.
In the multivariable regression models, one relevant
confounding variable was added at a time (Table 2).
Elevated values of CRP (>3 mg/l) (=0.10; P = 0.04)
and ESR (520 mm/h) (=0.12; P = 0.02) were still asso-
ciated with lower muscle strength after adjustment for
age, gender, comorbidities and NSAID use. However,
the associations between inflammatory markers and
muscle strength were no longer significant (CRP
= 0.04; P = 0.44 and ESR = 0.02; P = 0.67) when BMI
TABLE 2 Association of CRP and ESR with muscle
strength in patients with knee OA in multivariable














Linear regression analysis using muscle strength as depen-
dent factor. Crude model adjusted for aage, bgender, cco-
morbidities, dNSAID and eBMI.
TABLE 1 Associations of CRP and ESR with muscle





CRP + agea 0.15 0.02
CRP + gendera 0.09 0.07
CRP + comorbiditiesa 0.14 0.02
CRP + NSAIDa 0.12 0.05
CRP + BMIa 0.01 0.81
ESR 0.21 <0.001
ESR + agea 0.21 <0.001
ESR + gendera 0.13 0.01
ESR + comorbiditiesa 0.21 0.001
ESR + NSAIDa 0.20 0.001
ESR + BMIa 0.07 0.22
Linear regression analysis using muscle strength as depend-
ent factor. aAdjusted models.
TABLE 3 Baseline characteristics (n = 285)
Age, yearsa 61.7 (7.3)
Female, n (%) 179 (63)
Knee muscle strength, Nm/kga 0.9 (0.4)






NSAID use (yes), n (%) 40 (14)
BMIa, kg/m2 29.3 (5.6)
Radiographic OAb K/L score 52, n (%) 193 (67.7)
Inflammatory markers, median (IQR)
CRP, mg/l 2 (14)
ESR, mm/h 9 (415)
aMean (S.D.); bHighest knee score. K/L: KellgrenLawrence;
CIRS: Chronic Illness Rating Scale.




































was added to the models. A sensitivity analysis with CRP
cut-off point of 2 mg/l yielded the same conclusion (data
not shown).
Discussion
This study investigated the association of serum inflam-
matory markers (i.e. CRP and ESR) with muscle strength
in a group of patients with knee OA. We found that, in
patients with OA, elevated serum inflammatory markers
(i.e. CRP >3 mg/l and ESR520 mm/h) were associated
with lower knee muscle strength. Previous studies have
clearly documented the relationship between elevated
inflammatory markers and muscle weakness in patients
with RA [14, 33] and in older adults [15, 17]. However,
except for Wolfe [10] who previously studied the correla-
tion of ESR and CRP with hand grip strength in patients
with knee and hip OA, to the best of our knowledge this is
one of the first studies that described the association
between serum inflammatory markers (i.e. CRP and
ESR) and muscle strength in patients with established
diagnosis of knee OA.
The results of the present study are consistent with
Levinger et al. [20] who previously reported an association
between inflammation (IL-6) and knee muscle weakness
(extensors). However, the previous study was highly inva-
sive as it used inflammatory markers from muscle biop-
sies. It was carried out in a small population (n = 19) and its
results were not controlled for relevant confounders. On
the other hand, Santos et al. [21] did not find a significant
correlation between inflammatory markers in plasma (IL-6)
and knee muscle strength (extensors and flexors) in a
group of females with knee OA (n = 80). In contrast to
previous studies, in the present study serum inflammatory
markers that can be easily obtained in clinical practice
were analysed in a larger population of patients with
knee OA (n = 285). Even after adjustment for relevant con-
founders (i.e. age, sex, comorbidities and NSAID use) our
results showed statistically significant associations. As far
as we know, this is the largest study suggesting inflam-
mation as a possible factor influencing knee muscle
strength in this group of patients.
The relationship found between elevated inflammatory
markers and lower muscle strength is coherent with
findings of previous studies carried out in the general
elderly population, in which elevated levels of inflamma-
tory markers were associated not only with lower muscle
strength, but also with loss of muscle mass and sarcope-
nia [15, 17]. These associations might be explained by the
catabolic effect of inflammatory markers on muscle tissue
[34], and their possible influence on the decrease in
muscle regenerative potential [18]. Results from studies
carried out in rats suggested that inflammatory factors
might cause muscle breakdown [35, 36]. Moreover,
Bodell et al. [37] indicated that long exposure of skeletal
muscle to IL-6 can retard muscle growth in rats, possibly
due to the interaction with key growth factors. Although
these mechanisms have not been intensively studied in
humans, the same mechanism as found in rat models
might be involved in the development of muscle weakness
in humans.
Muscle strength was more strongly associated with
ESR (P< 0.001) than with CRP (P = 0.03). A possible
explanation might be the longer half-life of ESR in the
system compared with the rapid changes in concentration
of CRP. Although CRP and ESR are considered non-spe-
cific tests, their values can contribute to the detection of
diverse conditions associated with inflammation. Both
ESR and CRP are commonly used as markers of acute-
phase response of inflammation. However, CRP is more
sensitive than ESR to changes in the onset of acute-phase
response, increasing rapidly within hours of the stimulus,
and then returning to normal values following resolution.
After incorporating BMI to the adjusted model, the
associations of CRP and ESR with muscle weakness
were no longer significant. Obesity, a primary risk factor
for OA of the knee, has been associated with a condition
of low-grade inflammation that may contribute to progres-
sive joint degeneration [38, 39]. This relationship might be
explained by the possible production and secretion of
several pro-inflammatory cytokines by the adipose
tissue [40]. Another possible explanation may be asso-
ciated with the non-hepatic production of CRP through
the stimulation of adiposities by inflammatory cytokines
[41]. Previous studies have found a strong association
between systemic inflammatory markers and BMI [32,
42]. Moreover, BMI has been reported as an important
mediator in associations between CRP and ESR, and vari-
ous clinical characteristics in OA patients [32, 42, 43]. Due
to the link between obesity and inflammatory markers, the
adjustment of the associations for BMI might result in an
overcorrection of the model.
Some limitations to this study have to be considered.
First, with the cross-sectional design of the present study
we can only probe that associations exist, but it is not
possible to establish the causality underlying them.
Based on previous literature, we hypothesized that
elevated levels of inflammatory markers contribute to





































muscle weakness. However, longitudinal studies should
be undertaken to prove this hypothesis. Secondly,
although some relevant confounders were included, the
level of physical activity of the patients was not consid-
ered. As some studies have documented the positive
effect of physical activity in reducing the levels of inflam-
matory markers [44], it is possible that the associations
found in this study might be modified if the level of
physical activity of the participants were considered. A
key strength of our study is the use of serum inflammatory
markers that can be easily obtained in clinical practice
from a blood sample. Another strength of this study is
the large number of patients with knee OA (n = 285) stu-
died compared with previous studies related to inflamma-
tory markers and knee muscle strength [20, 21].
From a clinical perspective, given the relationship
between muscle strength and activity limitation in patients
with knee OA [2], the results of this study imply that, the-
oretically, controlling inflammation and reducing over-
weight in patients with knee OA might contribute to
better results in rehabilitation programmes, adding to the
improvement of muscle strength and subsequent
decrease in activity limitation. Nevertheless, intervention
research is needed to prove this hypothesis.
In conclusion, in patients with knee OA, elevated levels
of serum CRP and ESR were associated with lower knee
muscle strength. Moreover, the link between inflammation
and obesity might explain the effect that BMI has in the
association of inflammatory markers (i.e. CRP and ESR)
with muscle strength.
Rheumatology key messages
. Elevated CRP and ESR were significantly
associated with lower muscle strength in patients
with knee OA.
. BMI might influence the association between
inflammatory markers and muscle strength in
knee OA.
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